4-[2-(substituted benzylidene) hydrazino]-5, 6, 7-trialkoxy quinazoline compound and preparation method and application

Abstract

The invention discloses a 4-[2-(substituted benzylidene) hydrazino]-5, 6, 7-trialkoxy quinazoline compound and a preparation method and application thereof. 4-[2-(substituted benzylidene) hydrazino]-5, 6, 7-trialkoxy quinazoline compound has the structure shown as the following general form (I). According to the preparation method, 2, 3, 4-trihydroxybenzoic acid, dimethyl sulfate, diethyl sulfate, carbinol, sulfuric acid, nitric acid, hydrogen, formamide, phosphorus oxychloride, 80% of hydrazine hydrate and aromatic aldehyde are adopted as raw materials, and synthesized to obtain a series of novel 4-[2-(substituted benzylidene) hydrazino]-5, 6, 7-trialkoxy quinazoline compounds through eight steps; and such compounds have excellent antitumous effects and high effects on restraining the fungi of plant, and can be applied to preparing anti-cancer drugs and anti-plant fungal pesticides.

Description

technical field [0001] The invention relates to a preparation method and application of 4-[2-(substituted benzylidene)hydrazino]-5,6,7-trialkoxyquinazoline compounds with anticancer effects and anti-plant pathogens. Background technique [0002] Quinazoline compounds exhibit good biological activity and become one of the research hotspots of scholars in the fields of chemistry and biology. In terms of pesticides, quinazoline compounds have biological activities such as antibacterial, antiviral, and acaricidal. Among them, the fungicide Fluquinconazole (Fluquinconazole) is a broad-spectrum systemic fungicide, which has a good inhibitory effect on the biosynthesis of ergosterol. In terms of medicine, since Fry et al. discovered 4-anilinoquinazoline (PD 153035) as a specific inhibitor of EGFR tyrosine kinase in 1994, quinazoline compounds have developed the first generation and the second generation. Anticancer drugs targeting EGFR. The first-generation EGFR reversible inhib...

AI Technical Summary

Problems solved by technology

The combination therapy of Erlotinib with paclitaxel and carboplatin was carried out in the Phase III clinical trial, and it was found that the combination did not show obvious advantages

[0019] It can be seen from the background technology that quinazoline (ketone) derivatives have better biological activities such as insecticidal, antibacterial, and anticancer, but about 4-[2-(substituted benzylidene) hydrazino]-5 , 6,7-trialkoxyquinazoline compounds have not been synthesized at present, and there are relatively few research reports on the anti-phytopathogenic fungi and anti-cancer activities of these compounds at home and abroad.

Images